Nektar Therapeutics (NKTR) Operating Expenses: 2010-2025
Historic Operating Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to $43.5 million.
- Nektar Therapeutics' Operating Expenses fell 25.67% to $43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.7 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of $203.6 million for FY2024, which is 42.45% down from last year.
- Per Nektar Therapeutics' latest filing, its Operating Expenses stood at $43.5 million for Q3 2025, which was down 8.32% from $47.4 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Operating Expenses registered a high of $174.4 million during Q2 2022, and its lowest value of $14.8 million during Q4 2024.
- Its 3-year average for Operating Expenses is $63.9 million, with a median of $57.4 million in 2023.
- Its Operating Expenses has fluctuated over the past 5 years, first grew by 25.90% in 2022, then tumbled by 74.17% in 2024.
- Quarterly analysis of 5 years shows Nektar Therapeutics' Operating Expenses stood at $137.9 million in 2021, then crashed by 45.99% to $74.5 million in 2022, then fell by 22.95% to $57.4 million in 2023, then tumbled by 74.17% to $14.8 million in 2024, then fell by 25.67% to $43.5 million in 2025.
- Its Operating Expenses stands at $43.5 million for Q3 2025, versus $47.4 million for Q2 2025 and $55.0 million for Q1 2025.